Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41409-019-0652-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patients with Waldenström macroglobulinemia have impaired platelet and coagulation function.
Blood Adv
November 2024
Division of Genome Science and Cancer, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia.
Article Synopsis
- Patients with Waldenström macroglobulinemia (WM) experience symptoms like cytopenias, fatigue, and bleeding, often exacerbated by therapeutics like Bruton's tyrosine kinase inhibitors (BTKis).
- A study analyzed hemostatic dysfunction in WM patients, comparing samples from untreated patients, those on BTKis, and healthy donors, using various blood tests to assess platelet function and clotting potential.
- Results showed that WM patients had decreased platelet reticulation, slower thrombin generation, and impaired hemostatic function due to high levels of IgM, indicating serious disturbances in blood coagulation despite receiving treatment.
The Differences of Serum Thrombopoietin Levels Between Acquired Aplastic Anemia and Immune Thrombocytopenia in Pediatric Patients.
J Pediatr Hematol Oncol
August 2024
Hematologic Disease Laboratory, Hematology Center.
Thrombopoietin (TPO) is the critical regulator of platelet production. However, the role of TPO in pediatric patients with thrombocytopenic disorders has not been fully elucidated. In the present study, we attempted to investigate serum TPO levels in patients with acquired aplastic anemia (aAA) and immune thrombocytopenia (ITP).
View Article and Find Full Text PDFThe thrombopoietin mimetic JNJ-26366821 reduces the late injury and accelerates the onset of liver recovery after acetaminophen-induced liver injury in mice.
Arch Toxicol
June 2024
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, 3901 Rainbow Blvd, MS 1018, Kansas City, KS, 66160, USA.
Acetaminophen (APAP)-induced hepatotoxicity is comprised of an injury and recovery phase. While pharmacological interventions, such as N-acetylcysteine (NAC) and 4-methylpyrazole (4-MP), prevent injury there are no therapeutics that promote recovery. JNJ-26366821 (TPOm) is a novel thrombopoietin mimetic peptide with no sequence homology to endogenous thrombopoietin (TPO).
View Article and Find Full Text PDFEfficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.
Platelets
December 2023
Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
The conventional dose of recombinant human thrombopoietin (rhTPO) in the treatment of immune thrombocytopenia (ITP) is 300 U/kg per day, but the clinical reaction rate is not satisfactory. Accordingly, we explored the efficacy and safety of increasing rhTPO dose in the treatment of ITP. A retrospective study was conducted to collect the clinical data of 105 ITP patients who were divided into two groups, a low-dose group (15 000 U/day) and a high-dose group (30 000 U/day) according to the dose of rhTPO.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!